Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study.
Future Oncol
; 16(36): 3045-3060, 2020 Dec.
Article
in En
| MEDLINE
| ID: mdl-32885666
ABSTRACT
Aim:
Assessing treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma clinical practice. Materials &methods:
A US cross-sectional physician survey conducted February-September 2019.Results:
Surveyed physicians reported first-line treatment of 445 patients involving tyrosine kinase inhibitor monotherapy (51.0%), immuno-oncology (IO/IO combination) therapy (25.8%) or other regimens (23.1%). A total of 60.9% had physician-assessed IMDC risk. Of these 61.9, 50.9 and 27.6% of patients with favorable, intermediate and poor risk, respectively, received tyrosine kinase inhibitor monotherapy. A total of 16.7, 26.9 and 34.5% of patients with favorable, intermediate or poor risk received IO/IO combination therapy. Complete/partial responses (â¼35% patients) remained comparable across first-line treatments.Conclusion:
Guideline-recommended therapies are not widely prescribed. Many patients experienced poor clinical outcomes highlighting a need for more effective treatments.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Antineoplastic Combined Chemotherapy Protocols
/
Protein Kinase Inhibitors
/
Antineoplastic Agents, Immunological
/
Kidney Neoplasms
Type of study:
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Qualitative_research
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Future Oncol
Year:
2020
Type:
Article
Affiliation country:
United kingdom